Palmitoleic acid

Palmitoleic acid is a monounsaturated omega-7 fatty acid (16:1n-7) produced primarily in adipose tissue and the liver via stearoyl-CoA desaturase-1 (SCD-1). It acts as a lipokine signaling molecule, influencing insulin sensitivity, glucose metabolism, and inflammatory pathways across multiple organ systems.

Origin & History

Palmitoleic acid is an omega-7 monounsaturated fatty acid (C16H30O2) found naturally in human adipose tissue, liver, and blood plasma. It is commercially extracted from macadamia oil (Macadamia integrifolia), sea buckthorn oil, and marine oils containing 15-20% concentration, and can also be biosynthesized endogenously from palmitic acid via delta-9 desaturase enzyme.

Historical & Cultural Context

No historical or traditional medicinal uses are documented in the research dossier. The compound appears to be primarily studied in modern biochemical contexts.

Health Benefits

• May enhance insulin sensitivity by suppressing inflammation (biochemical evidence only, no human trials cited)
• Potentially protects pancreatic beta cells from destruction (mechanism suggested but no clinical evidence provided)
• Functions as a lipokine signaling molecule in adipose tissue (theoretical benefit, no clinical studies)
• Limited evidence prevents specific health benefit claims
• Research dossier lacks human clinical trial data to support therapeutic uses

How It Works

Palmitoleic acid activates PPAR-alpha and PPAR-gamma nuclear receptors, modulating genes involved in fatty acid oxidation and glucose uptake in skeletal muscle and liver cells. As a lipokine, it is secreted by adipocytes and acts on distant tissues to suppress NF-kB-mediated inflammatory signaling, potentially reducing TNF-alpha and IL-6 production. It also inhibits ceramide accumulation and endoplasmic reticulum stress in pancreatic beta cells, preserving insulin secretion capacity.

Scientific Research

The research dossier contains no human clinical trials, randomized controlled trials, or meta-analyses with PubMed PMIDs. Only biochemical mechanisms are mentioned regarding insulin sensitivity and beta cell protection, but these are not tied to specific human studies.

Clinical Summary

Human clinical evidence for isolated palmitoleic acid supplementation remains limited; most data derives from in vitro studies and animal models rather than randomized controlled trials. Observational studies correlating serum palmitoleic acid levels with improved insulin sensitivity and reduced metabolic syndrome markers exist but cannot establish causation. Small pilot trials using sea buckthorn oil or macadamia nut oil as dietary sources rich in palmitoleic acid have shown modest improvements in lipid profiles, though sample sizes typically range from 20 to 60 participants. Overall, the evidence base is preliminary, and definitive human trials isolating palmitoleic acid as an independent intervention are lacking.

Nutritional Profile

Palmitoleic acid (16:1n-7) is a monounsaturated omega-7 fatty acid found naturally in macadamia nuts (~17-22% of fat content), sea buckthorn oil (~19-29%), and cold-water fish oils (~1-4%). As a fatty acid, it provides approximately 9 kcal/g. It contains no vitamins, minerals, fiber, or protein. Bioactive concentration in supplements typically ranges from 200-500mg per serving. It functions primarily as a lipokine — a lipid signaling molecule secreted by adipose tissue that communicates metabolically with liver, muscle, and pancreatic tissues. Bioavailability is moderate-to-good when consumed with food due to its lipid-soluble nature; absorption occurs via chylomicron packaging in the small intestine. It is found endogenously in human plasma at concentrations of approximately 50-150 µmol/L, with levels correlating to metabolic status. Stearoyl-CoA desaturase (SCD-1) is the primary enzyme responsible for its endogenous synthesis from palmitic acid.

Preparation & Dosage

No clinically studied dosage ranges, standardized forms, or preparation methods are documented in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Palmitoleic acid pairs notably with EPA and DHA (omega-3 fatty acids), where complementary anti-inflammatory pathways — omega-7 modulating NF-κB signaling and omega-3s producing resolvins and protectins — may create additive effects on insulin sensitivity and systemic inflammation reduction. Berberine is a mechanistically relevant partner, as both compounds appear to target AMPK activation and glucose uptake pathways in skeletal muscle and hepatic tissue, potentially offering complementary support for metabolic function. Tocotrienols (particularly from annatto or palm oil) synergize with palmitoleic acid by providing lipid-phase antioxidant protection that prevents peroxidation of the fatty acid before it can exert its lipokine signaling role, while also independently supporting pancreatic beta-cell health through their own anti-apoptotic mechanisms.

Safety & Interactions

Palmitoleic acid is generally considered safe when consumed through dietary sources such as macadamia nuts, sea buckthorn, or fish oils, with no established tolerable upper intake level. High-dose supplementation may theoretically increase LDL-C in susceptible individuals, as some studies on palmitate-related fatty acids suggest modest pro-atherogenic potential at excessive intakes. Individuals on anticoagulant medications such as warfarin should exercise caution, as omega fatty acids can potentiate antiplatelet effects and alter INR readings. Safety during pregnancy and lactation has not been systematically evaluated for concentrated palmitoleic acid supplements, making dietary food sources preferable for these populations.